Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
IRADIMED CORP reported the second quarter of 2023 results: revenue $15.6 million to $15.8 million, EPS $0.27 to $0.29. Guidance initiated.
- Period
- the second quarter of 2023
- Revenue
- $15.6 million to $15.8 million
- EPS
- $0.27 to $0.29
- Guidance
- initiated
- Result
- guidance update
Exact text from the filing
For the second quarter of 2023, the Company expects to report revenue of $15.6 million to $15.8 million, GAAP diluted earnings per share of $0.27 to $0.29, and non-GAAP diluted earnings per share of $0.30 to $0.32.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
IRADIMED CORP reported the first quarter ended March 31, 2023 results: revenue $15.5 million, net income $3.4 million, EPS $0.27 per diluted share.
- Period
- the first quarter ended March 31, 2023
- Revenue
- $15.5 million
- Net income
- $3.4 million
- EPS
- $0.27 per diluted share
- Result
- reported results
Exact text from the filing
For the first quarter ended March 31, 2023, the Company reported over 25% year-over-year revenue growth to $15.5 million compared to $12.3 million for the first quarter of 2022. Net income was $3.4 million, or $0.27 per diluted share, compared to $2.5 million, or $0.20 per diluted share for the first quarter of 2022.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
IRADIMED CORP reported full-year 2023 results: revenue $62 million to $63.5 million, EPS $1.13 to $1.21. Guidance raised.
- Period
- full-year 2023
- Revenue
- $62 million to $63.5 million
- EPS
- $1.13 to $1.21
- Guidance
- raised
- Result
- guidance update
Exact text from the filing
The Company increased its full-year 2023 financial guidance and now expects to report revenue of $62 million to $63.5 million, GAAP diluted earnings per share of $1.13 to $1.21, and non-GAAP diluted earnings per share of $1.26 to $1.35.
View on SEC.gov